Key data
Open—
From 52W high—
Volume—
Market cap—
P/E (TTM)—
P/S (TTM)—
Div yield—
Key data
Open
—
From 52W high
—
Volume
—
Market cap
—
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
—
P/E (TTM)
—
RSI (14)
—
MomentumView details →
1D Return
—
YTD Return
—
SummaryUpdated Jun 1, 2026
Profound Medical Corp. (NASDAQ:PROF) is a Canadian commercial-stage medical device company founded in 2008 and headquartered in Mississauga, Ontario. The company went public on NASDAQ in October 2019, following earlier listings on the Toronto Stock Exchange. Profound Medical specializes in developing and commercializing magnetic resonance-guided ablation procedures for treating various medical conditions, with its primary focus on prostate diseases, uterine fibroids, and palliative pain treatment. The company operates primarily in Canada, the United States, Germany, and Finland, representing a specialized player in the emerging field of MR-guided focused ultrasound therapy.
Latest newsMore news →
Profound Medical Corp. announced a role change for Mathieu Burtnyk to Chief Technology Officer, effective September 1, 2026.17d agoProfound Medical Corp. appointed Richard Fabian as its new President, effective immediately.19d agoProfound introduced new real-time interventional MRI software (TDC) that enables customers to perform up to 6 TULSA Procedures per system per day.34d ago